A Randomized Trial of a Low-Trapping Nonselective N-Methyl-D-Aspartate Channel Blocker in Major Depression
暂无分享,去创建一个
Carlos A. Zarate | David A. Luckenbaugh | Lobna Ibrahim | D. Luckenbaugh | C. Zarate | Mark A. Smith | N. Brutsche | Craig A. Marquardt | Daniel C. Mathews | Daniel Mathews | Jose Franco Chaves | Craig Marquardt | Immaculata Ukoh | Libby Jolkovsky | Nancy E. Brutsche | Lobna A Ibrahim | L. Jolkovsky | Immaculata Ukoh | C. Marquardt
[1] Dennis S. Charney,et al. Ketamine for Depression: Where Do We Go from Here? , 2012, Biological Psychiatry.
[2] G. Laje,et al. Relationship of Ketamine's Plasma Metabolites with Response, Diagnosis, and Side Effects in Major Depression , 2012, Biological Psychiatry.
[3] D. Luckenbaugh,et al. A Randomized, Placebo-Controlled, Crossover Pilot Trial of the Oral Selective NR2B Antagonist MK-0657 in Patients With Treatment-Resistant Major Depressive Disorder , 2012, Journal of clinical psychopharmacology.
[4] D. Luckenbaugh,et al. Replication of Ketamine's Antidepressant Efficacy in Bipolar Depression: A Randomized Controlled Add-On Trial , 2012, Biological Psychiatry.
[5] D. Luckenbaugh,et al. Rapid antidepressant changes with sleep deprivation in major depressive disorder are associated with changes in vascular endothelial growth factor (VEGF): A pilot study , 2011, Brain Research Bulletin.
[6] E. Kavalali,et al. NMDA Receptor Blockade at Rest Triggers Rapid Behavioural Antidepressant Responses , 2011, Nature.
[7] J. Krystal,et al. The antidepressant effect of ketamine is not associated with changes in occipital amino acid neurotransmitter content as measured by [1H]-MRS , 2011, Psychiatry Research: Neuroimaging.
[8] L. Harrington,et al. Glycogen Synthase Kinase-3 Is an Early Determinant in the Differentiation of Pathogenic Th17 Cells , 2011, The Journal of Immunology.
[9] Nanxin Li,et al. mTOR-Dependent Synapse Formation Underlies the Rapid Antidepressant Effects of NMDA Antagonists , 2010, Science.
[10] D. Luckenbaugh,et al. A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression. , 2010, Archives of general psychiatry.
[11] D. Charney,et al. Safety and Efficacy of Repeated-Dose Intravenous Ketamine for Treatment-Resistant Depression , 2010, Biological Psychiatry.
[12] M. Kano,et al. Involvement of NMDAR2A tyrosine phosphorylation in depression‐related behaviour , 2009, The EMBO journal.
[13] P. Skolnick,et al. Glutamate-based antidepressants: 20 years on. , 2009, Trends in pharmacological sciences.
[14] C. Stockmeier,et al. Reduced levels of NR2A and NR2B subunits of NMDA receptor and PSD-95 in the prefrontal cortex in major depression , 2009, Progress in Neuro-Psychopharmacology and Biological Psychiatry.
[15] A. Placentino,et al. VEGF serum levels in depressed patients during SSRI antidepressant treatment , 2009, Progress in Neuro-Psychopharmacology and Biological Psychiatry.
[16] T. Insel,et al. The STAR*D trial: revealing the need for better treatments. , 2009, Psychiatric services.
[17] M. Krams,et al. An Innovative Design to Establish Proof of Concept of the Antidepressant Effects of the NR2B Subunit Selective N-Methyl-D-Aspartate Antagonist, CP-101,606, in Patients With Treatment-Refractory Major Depressive Disorder , 2008, Journal of clinical psychopharmacology.
[18] D. Luckenbaugh,et al. Rapid onset of antidepressant action: a new paradigm in the research and treatment of major depressive disorder. , 2008, The Journal of clinical psychiatry.
[19] I. Heuser,et al. Serum Concentrations of Nerve Growth Factor and Brain-Derived Neurotrophic Factor in Depressed Patients before and after Antidepressant Treatment , 2008, Pharmacopsychiatry.
[20] Guang Chen,et al. Cellular Mechanisms Underlying the Antidepressant Effects of Ketamine: Role of α-Amino-3-Hydroxy-5-Methylisoxazole-4-Propionic Acid Receptors , 2008, Biological Psychiatry.
[21] Hongwei Song,et al. Gene expression and association analysis of vascular endothelial growth factor in major depressive disorder , 2007, Progress in Neuro-Psychopharmacology and Biological Psychiatry.
[22] Paul J Carlson,et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. , 2006, Archives of general psychiatry.
[23] J. Witkin,et al. Sensitive and rapid behavioral differentiation ofN-methyl-d-aspartate receptor antagonists , 1994, Psychopharmacology.
[24] M. First,et al. Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research version (SCID-I RV) , 2002 .
[25] K. Lees,et al. Tolerability of the Low-Affinity, Use-Dependent NMDA Antagonist AR-R15896AR in Stroke Patients: A Dose-Ranging Study , 2001, Stroke.
[26] H. Sackeim,et al. The definition and meaning of treatment-resistant depression. , 2001, The Journal of clinical psychiatry.
[27] J. Krystal,et al. Attenuation of the neuropsychiatric effects of ketamine with lamotrigine: support for hyperglutamatergic effects of N-methyl-D-aspartate receptor antagonists. , 2000, Archives of general psychiatry.
[28] John H Krystal,et al. Antidepressant effects of ketamine in depressed patients , 2000, Biological Psychiatry.
[29] D DeBrota,et al. The responsiveness of the Hamilton Depression Rating Scale. , 2000, Journal of psychiatric research.
[30] G. Mealing,et al. Differences in degree of trapping of low-affinity uncompetitive N-methyl-D-aspartic acid receptor antagonists with similar kinetics of block. , 1999, The Journal of pharmacology and experimental therapeutics.
[31] S. Southwick,et al. Measurement of Dissociative States with the Clinician-Administered Dissociative States Scale (CADSS) , 1998, Journal of traumatic stress.
[32] J. Peeling,et al. Low‐Affinity NMDA Receptor Antagonists , 1997 .
[33] D. Monaghan,et al. NR1 and NR2 subunit contributions to N-methyl-D-aspartate receptor channel blocker pharmacology. , 1997, The Journal of pharmacology and experimental therapeutics.
[34] J. Peeling,et al. Low-affinity NMDA receptor antagonists. The neuroprotective potential of ARL 15896AR. , 1997, Annals of the New York Academy of Sciences.
[35] R. Duman,et al. Regulation of BDNF and trkB mRNA in rat brain by chronic electroconvulsive seizure and antidepressant drug treatments , 1995, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[36] C. Parsons,et al. Comparison of the potency, kinetics and voltage-dependency of a series of uncompetitive NMDA receptor antagonists in vitro with anticonvulsive and motor impairment activity in vivo , 1995, Neuropharmacology.
[37] J. Krystal,et al. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. , 1994, Archives of general psychiatry.
[38] P Bech,et al. The Hamilton Depression Scale , 1981, Acta psychiatrica Scandinavica.
[39] A. Beck,et al. Assessment of suicidal intention: the Scale for Suicide Ideation. , 1979, Journal of consulting and clinical psychology.
[40] R. C. Young,et al. A Rating Scale for Mania: Reliability, Validity and Sensitivity , 1978, British Journal of Psychiatry.
[41] P. Bech,et al. QUANTITATIVE RATING OF DEPRESSIVE STATES , 1975, Acta psychiatrica Scandinavica.
[42] A. Beck,et al. Assessment of depression: the depression inventory. , 1974, Modern problems of pharmacopsychiatry.
[43] R. Aitken. Measurement of feelings using visual analogue scales. , 1969, Proceedings of the Royal Society of Medicine.
[44] J. Overall,et al. The Brief Psychiatric Rating Scale , 1962 .
[45] M. Hamilton. A RATING SCALE FOR DEPRESSION , 1960, Journal of neurology, neurosurgery, and psychiatry.
[46] M. Hamilton. The assessment of anxiety states by rating. , 1959, The British journal of medical psychology.